Suzhou Forlong Biotechnology Co.
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Suzhou Forlong Biotechnology Co. sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).
Suzhou Forlong Biotechnology Co.: 1 sponsored US clinical trial, none currently recruiting.
Suzhou Forlong Biotechnology Co. sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Locally Advanced/Metastatic Solid Tumors, with 1 trials.
Mid-pack sponsor footprint
Suzhou Forlong Biotechnology Co. is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
How the Suzhou Forlong Biotechnology Co. early-phase archive is shaped
1 indexed studies, none listed as recruiting (0% open); 1 completed (100%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Locally Advanced/Metastatic Solid Tumors (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Suzhou Forlong Biotechnology Co.: archived-pipeline peers nationwide
Peers matched on 1 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Suzhou Forlong Biotechnology Co. sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1 archived trials
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Suzhou Forlong Biotechnology Co. page
1 registered trials is a research-attention snapshot, not an endorsement of Suzhou Forlong Biotechnology Co. or any single study.
- None of Suzhou Forlong Biotechnology Co.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Locally Advanced/Metastatic Solid Tumors is the condition Suzhou Forlong Biotechnology Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Locally Advanced/Metastatic Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Suzhou Forlong Biotechnology Co. pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.